UBS Group Initiates Coverage on Elanco Animal Health (NYSE:ELAN)

UBS Group assumed coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $18.00 price target on the stock. UBS Group’s price target suggests a potential upside of 44.87% from the company’s previous close.

ELAN has been the subject of a number of other research reports. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Barclays boosted their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $16.75.

Elanco Animal Health Trading Down 3.5 %

Shares of ELAN opened at $12.43 on Monday. The stock has a fifty day moving average price of $13.35 and a two-hundred day moving average price of $14.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 52-week low of $11.40 and a 52-week high of $18.80. The company has a market cap of $6.14 billion, a price-to-earnings ratio of 31.06, a PEG ratio of 2.02 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s quarterly revenue was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.18 earnings per share. Analysts predict that Elanco Animal Health will post 0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. raised its position in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the period. ORG Wealth Partners LLC acquired a new stake in shares of Elanco Animal Health during the third quarter worth about $29,000. nVerses Capital LLC acquired a new stake in shares of Elanco Animal Health during the second quarter worth about $32,000. ORG Partners LLC acquired a new stake in shares of Elanco Animal Health during the second quarter worth about $31,000. Finally, AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the third quarter worth about $34,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.